Full history for every metric is available with a Kvantra account
BiVictriX Therapeutics Plc (BVX.L)
Key financial summary
Financials in GBP| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | £m | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | £m | -3 | -3 | |||||
| Net profit | £m | -0 | -0 | -0 | -2 | -2 | -3 | -3 |
| EPS reported | £ | -0.04 | -0.04 | |||||
| Operating cashflow per share | £ | -0.03 | -0.03 | |||||
| Capex per share | £ | 0.00 | 0.00 | |||||
| FCF per share | £ | -0.03 | -0.03 | |||||
| Free cash flow | £m | -2 | -2 | |||||
| Net debt | £m | -3 | -2 | |||||
| Book value equity | £m | 4 | 2 | |||||
| Book value per share | £ | 0.05 | 0.03 | |||||
| Number of shares | m | 72.65 | 72.65 | |||||
| DPS (TTM paid) | £ | 0.00 | 0.00 |
Financial summary
Financials in GBP| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 2.16 | 3.58 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -3.93 | -3.96 | |||||
| EV/EBITDA LTM | x | -1.61 | -2.13 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -33.37% | -35.03% | |||||
| FCF Yield | % | -25.47% | -25.25% | |||||
| Quality | ||||||||
| ROE | % | -71.95% | -67.92% | |||||
| ROIC | % | -67.48% | -67.48% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -7.42 | -10.27 | |||||
| Net Debt/EBITDA | x | 1.05 | 1.05 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -42.99% | -19.06% | |||||
| Net debt/Equity | x | -0.93 | -0.68 | |||||
| Gross debt/equity | x | 0.07 | 0.09 | |||||
Company overview
BiVictriX Therapeutics Plc is a United Kingdom-based biotechnology firm dedicated to pioneering innovative treatments for cancer. The company's core technology involves its distinctive Bi-Cygni therapeutics, which are engineered to precisely identify and combat specific cancer types. Their foremost development program, BVX001, is currently being advanced to address acute myeloid leukaemia. Established in 2016 as BiVictriX Plc, the organization officially adopted its present name, BiVictriX Therapeutics Plc, in August 2021. Its corporate headquarters are located in Macclesfield, United Kingdom.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
BiVictriX Therapeutics Plc (BVX.L)
BiVictriX Therapeutics Plc is a United Kingdom-based biotechnology firm dedicated to pioneering innovative treatments for cancer. The company's core technology involves its distinctive Bi-Cygni therapeutics, which are engineered to precisely identify and combat specific cancer types. Their foremost development program, BVX001, is currently being advanced to address acute myeloid leukaemia. Established in 2016 as BiVictriX Plc, the organization officially adopted its present name, BiVictriX Therapeutics Plc, in August 2021. Its corporate headquarters are located in Macclesfield, United Kingdom.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free